2024 World Conference on Lung Cancer (WCLC) - Posters-P4.17F.04 Feasibility of Comprehensive Genomic Profiling for Advanced NSCLC in Public Healthcare System

P4.17F.04 Feasibility of Comprehensive Genomic Profiling for Advanced NSCLC in Public Healthcare System - The Hong Kong Experience

Back to course

Pdf Summary

The document discusses the feasibility and acceptance of Comprehensive Genomic Profiling (CGP) for advanced non-small cell lung cancer (NSCLC) within the public healthcare system in Hong Kong. Lung cancer remains the most prevalent cancer globally, prompting the need for effective diagnostic and therapeutic strategies, including FDA-approved targeted therapies.<br /><br />The study, spearheaded by a collaboration among several Hong Kong hospitals and the University of Hong Kong, has been implementing CGP testing across seven public cancer centers since 2021. The routine integration of CGP into patient management aims to enhance the detection rate of actionable mutations while maintaining comparable turnaround times to existing testing methods. <br /><br />A survey of 21 thoracic oncologists reveals strong clinician acceptance of CGP, particularly due to its effectiveness in identifying a wider range of actionable mutations, which can improve therapy identification compared to the standard assay. Notably, CGP has been welcomed for its potential to predict treatment effects and aid in patient prognostication. The study reported a high success rate of CGP with 95.2% of tests yielding usable results and a significant identification rate of druggable mutations (65.3%).<br /><br />The document notes that the median additional time required for clinicians to explain CGP details to patients is reasonable (5-10 minutes), and the CGP turnaround time of 2-3 weeks is comparable to traditional gene-based testing. The study, funded by Roche Hong Kong Limited, demonstrated that 72.5% of patients presented with other cancer-associated mutations which could be crucial for prognosis. There is no conflict of interest declared by the authors, emphasizing objective analysis and findings. Overall, the report highlights the promising role of CGP in advancing personalized medicine for NSCLC patients in public healthcare settings.

Asset Subtitle

Ka Man Cheung

Meta Tag

Speaker Ka Man Cheung

Topic Global Health, Health Services & Health Economics

Keywords

Comprehensive Genomic Profiling

non-small cell lung cancer

NSCLC

Hong Kong

public healthcare

actionable mutations

targeted therapies

oncologist acceptance

personalized medicine

Roche Hong Kong Limited